As biopharmaceutical organizations explore the use of Antibody Drug Conjugates (ADC) as a class of cancer therapies, significant challenges are found in analyzing their complex, heterogeneous structures. The determination of drug-to-antibody ratios (DAR) and sites of conjugation present unique analytical challenges that can be addressed with Waters' fit-for-purpose UPLC, QTof MS and informatics solutions.
Liuxi Chen, Senior Scientist at Waters Corporation, presents at ASMS 2015. In-depth characterization of lysine-conjugated antibody-drug conjugates (ADCs) by a multiplexed MS/MS data acquisition strategy combined with multi-enzyme digestion.
|
View the poster presented at ASMS 2015 entitled, Localizing Conjugation Sites of Cysteine-Conjugated Antibody Drug Conjugates by Improved LC-MS Subunit Analysis for ADC Positional Isomer Identification. |
Development of Integrated Informatics Workflows for the Automated Assessment of Comparability for Antibody Drug Conjugates (ADCs) using LC-UV and LC-UV/MS. Features the Waters Protein-Pak Hi Res HIC Column and UNIFI Software. |
As a part of Bioanalysis Zone's Spotlight on ADCs, Waters Corporation's resident ADC expert, John Gebler, provides a presentation on Advanced Characterization of Antibody Drug Conjugates (ADCs) by Liquid Chromatography and Mass Spectrometry (LC/MS).
|
In Bioanalysis Zone's Spotlight on ADCs, John Gebler of Waters Corporation, is part of an expert panel discussion, analyzing results from Bioanalysis Zone's ADC survey, providing advice on how to carry out bioanalysis of ADCs and answering questions from the audience.
|
As a part of Bioanalysis Zone's Spotlight on ADCs, Brian Rago with Pfizer is interviewed on ADC bioanalysis and how the community can overcome the associated challenges.
|
April Xu, Senior Principal Scientist in Pfizer's BioTherapeutics Pharmaceutical Sciences group, spoke at ASMS 2014 on the approach her group takes to overcoming challenges in analyzing ADCs with UPLC, QTof-MS, and informatics solutions from Waters. Watch scientific case study by Pfizer
|
Want to share our video on how to characterize Antibody Drug Conjugates (ADCs) using UPLC, QTof-MS, and informatics? Download the video file (.mov, 232 MB). |
Weibin Chen, Senior Scientific Manager in Waters Biopharmaceutical Business team, gives his poster, Development of Integrated Informatics Workflows for the Automated Assessment of Comparability for ADCs Using LC/UV and LC/UV/MS. |
Igenica Biotherapeutics Turns to Waters to Accelerate Antibody Drug Conjugate (ADC) Development. Learn why Igenica selected the Waters Biopharmaceutical Platform Solution with UNIFI to support their ADC characterization studies.
|
Join the conversation on Linked In: Antibody Drug Conjugates Group
What are ADCs? Video by ADC Review
C&EN Cover Story: Building Antibody-Drug Conjugates
On-demand webinar: ADME of ADCs
DMPK and Bioanalysis Knowledge Center
Dr. Beck has contributed to the R&D of anticancer mAbs, vaccines and peptides.
View Dr. Beck's citations
At our November 2014 ADC Meeting, hosted in Wilmlsow, UK, Dr. Beck spoke on analytical and bioanalytical challenges of ADCs.
View Presentation by Dr. Alain Beck